Sarepta Therapeutics announced last month a collaboration with University College London for the development of an exon-skipping drug targeting
exon 53, its fourth drug in development, in support of Sarepta’s broad-based program for the treatment of Duchenne muscular dystrophy (DMD)
In recent years, significant work has been dedicated to
studying the half-life of drugs, and while researchers have been successful in lengthening the half-life of proteins and peptides, they have yet to find a
way to tailor the pharmacokinetics of certain drugs to specific medical needs.”
If you want minimal results, resolve to do the bare minimum. If you want surprising results--results that set tongues to wagging and produce spikes in your stock price--you’ll need to think "outside of the box."